Discovery

HotSpot Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

SR One fuels HotSpot's $65M B round to fund allosteric R&D

Lead Product(s): Undisclosed

Therapeutic Area: Immunology

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: S.R. One

Deal Size: $65.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing May 21, 2020

Details:

The Series B financing will support the advancement of HotSpot’s lead programs to the clinic, including protein kinase C (PKC-theta) antagonists for Th2 and T-reg driven autoimmune disease and S6 kinase (S6K) antagonists for rare metabolic disease.

Dyno Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference

Lead Product(s): Synthetic AAV capsids Proteins

Therapeutic Area: Immunology

Highest Development Status: Discovery Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

The presentation will highlight results from Dyno's study on Artificial intelligence powered design of synthetic AAV capsids without pre-existing immunity for the universal treatment of all patients.

Iontas

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

IONTAS Announces a New Collaboration to Identify Novel Immunotherapy Targets with Inotrem

Lead Product(s): Antibodies

Therapeutic Area: Immunology

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Inotrem S.A

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 07, 2020

Details:

As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.

Ventus Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Ventus Uncloaks with $60M to Target the Innate immune System

Lead Product(s): Undisclosed

Therapeutic Area: Immunology

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Versant Ventures

Deal Size: $60.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing May 06, 2020

Details:

Proceeds will be used to advance three pipeline programs and to expand the company’s structural immunology platform to pursue previously intractable drug targets.

Ryvu Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

POLAND Poland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Galapagos and Ryvu Announce Research Collaboration

Lead Product(s): Undisclosed

Therapeutic Area: Immunology

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Galapagos

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 16, 2020

Details:

In this joint reaserch collaboration, Ryvu is responsible for early drug discovery. Galapagos will have an exclusive option to license IP developed by Ryvu.